Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPTNASDAQ:EXAINASDAQ:INBXNASDAQ:RGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$9.14+2.4%$8.25$2.99▼$10.28$1.39B1.751.57 million shs1.38 million shsEXAIExscientia$4.84$4.97$3.80▼$6.49$632.93M0.83654,123 shsN/AINBXInhibrx$13.13+2.1%$12.46$10.80▼$34.58$190.07MN/A156,523 shs100,655 shsRGNXREGENXBIO$9.07-6.6%$7.86$5.04▼$15.39$487.05M1.11886,153 shs1.68 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies+2.35%-2.35%+15.70%+9.33%+165.70%EXAIExscientia0.00%0.00%0.00%0.00%+3.20%INBXInhibrx+2.10%+0.46%+7.10%+4.21%-61.54%RGNXREGENXBIO-6.59%-9.30%-0.87%+35.98%-39.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADPTAdaptive Biotechnologies3.5821 of 5 stars1.44.00.04.24.32.50.6EXAIExscientia0.1298 of 5 stars1.00.00.00.00.01.70.6INBXInhibrx2.2423 of 5 stars0.02.00.04.63.02.51.3RGNXREGENXBIO4.2352 of 5 stars3.42.00.04.62.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.83Moderate Buy$9.837.59% UpsideEXAIExscientia 2.00Hold$5.003.31% UpsideINBXInhibrx 2.00HoldN/AN/ARGNXREGENXBIO 2.83Moderate Buy$31.63248.68% UpsideCurrent Analyst Ratings BreakdownLatest EXAI, RGNX, INBX, and ADPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025INBXInhibrxJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/6/2025ADPTAdaptive BiotechnologiesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$11.00 ➝ $13.005/5/2025ADPTAdaptive BiotechnologiesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$7.00 ➝ $9.005/2/2025ADPTAdaptive BiotechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $10.004/17/2025RGNXREGENXBIOThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.003/21/2025ADPTAdaptive BiotechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$8.00 ➝ $9.003/20/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.00 ➝ $52.003/18/2025RGNXREGENXBIOLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$24.003/17/2025RGNXREGENXBIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $34.003/14/2025RGNXREGENXBIOMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$22.00 ➝ $24.003/14/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.00 ➝ $52.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$189.53M7.33N/AN/A$1.37 per share6.67EXAIExscientia$25.60M24.72N/AN/A$2.54 per share1.91INBXInhibrx$200K950.35N/AN/AN/A∞RGNXREGENXBIO$156.72M2.90N/AN/A$7.09 per share1.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$159.49M-$0.96N/AN/AN/A-89.12%-64.65%-26.45%8/7/2025 (Estimated)EXAIExscientia-$181.56M-$1.51N/AN/AN/A-882.09%-49.10%-33.13%N/AINBXInhibrx-$154.96M$116.750.11N/AN/AN/A-113.74%-80.56%6/16/2025 (Estimated)RGNXREGENXBIO-$263.49M-$3.11N/AN/AN/A-283.19%-70.65%-41.68%8/7/2025 (Estimated)Latest EXAI, RGNX, INBX, and ADPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q4 2024INBXInhibrx-$2.55-$2.80-$0.25-$2.80N/AN/A5/12/2025Q1 2025RGNXREGENXBIO$0.41$0.12-$0.29$0.12$105.35 million$89.01 million5/1/2025Q1 2025ADPTAdaptive Biotechnologies-$0.28-$0.20+$0.08-$0.20$42.13 million$52.44 million3/17/2025Q4 2024INBXInhibrx-$2.88-$3.09-$0.21-$3.09N/A$0.10 million3/13/2025Q4 2024RGNXREGENXBIO-$1.27-$1.01+$0.26-$1.01$23.70 million$21.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/AEXAIExscientiaN/AN/AN/AN/AN/AINBXInhibrxN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A2.892.81EXAIExscientia0.064.544.54INBXInhibrxN/A4.704.70RGNXREGENXBION/A3.053.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%EXAIExscientia41.58%INBXInhibrx82.46%RGNXREGENXBIO88.08%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies6.40%EXAIExscientia16.40%INBXInhibrx17.09%RGNXREGENXBIO12.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790151.92 million138.43 millionOptionableEXAIExscientia280130.77 million109.32 millionOptionableINBXInhibrx16614.48 million11.26 millionOptionableRGNXREGENXBIO37050.16 million43.04 millionOptionableEXAI, RGNX, INBX, and ADPT HeadlinesRecent News About These CompaniesMillennium Management LLC Buys 1,061,187 Shares of REGENXBIO Inc. (NASDAQ:RGNX)May 26 at 3:53 AM | marketbeat.comBNP Paribas Financial Markets Acquires 75,652 Shares of REGENXBIO Inc. (NASDAQ:RGNX)May 25 at 3:18 AM | marketbeat.comQ2 Earnings Forecast for REGENXBIO Issued By Leerink PartnrsMay 24, 2025 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Shares Purchased by Jane Street Group LLCMay 23, 2025 | marketbeat.comRegenxbio at RBC Conference: Strategic Moves and Clinical ProgressMay 22, 2025 | investing.comREGENXBIO FY2025 EPS Forecast Reduced by Chardan CapitalMay 21, 2025 | marketbeat.comREGENXBIO Inc.: REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 MillionMay 20, 2025 | finanznachrichten.deREGENXBIO announces royalty monetization agreement for up to $250MMay 20, 2025 | msn.comREGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 MillionMay 19, 2025 | prnewswire.comFY2025 EPS Estimate for REGENXBIO Decreased by AnalystMay 19, 2025 | americanbankingnews.comPoint72 Asia Singapore Pte. Ltd. Makes New $447,000 Investment in REGENXBIO Inc. (NASDAQ:RGNX)May 18, 2025 | marketbeat.comHudson Bay Capital Management LP Has $2.38 Million Position in REGENXBIO Inc. (NASDAQ:RGNX)May 16, 2025 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Director Sells $162,961.82 in StockMay 15, 2025 | insidertrades.comUS FDA accepts and grants priority review status to Regenxbio’s BLA for clemidsogene lanparvovec to treat Mucopolysaccharidosis IIMay 15, 2025 | pharmabiz.comEarnings Miss: REGENXBIO Inc. Missed EPS By 64% And Analysts Are Revising Their ForecastsMay 15, 2025 | finance.yahoo.comFDA Accepts Biologics License Application for Mucopolysaccharidosis II TreatmentMay 14, 2025 | prnewswire.comREGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Integral Health Asset Management LLCMay 14, 2025 | marketbeat.comFDA Grants Regenxbio Priority Review for MPS II Gene Therapy Regulatory ApplicationMay 13, 2025 | precisionmedicineonline.comRegenxbio stock rises on FDA’s priority review for MPS II therapyMay 13, 2025 | investing.comREGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS IIMay 13, 2025 | prnewswire.comCubist Systematic Strategies LLC Makes New $2.79 Million Investment in REGENXBIO Inc. (NASDAQ:RGNX)May 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEXAI, RGNX, INBX, and ADPT Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$9.14 +0.21 (+2.35%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$9.16 +0.02 (+0.22%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Exscientia NASDAQ:EXAIExscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.Inhibrx NASDAQ:INBX$13.13 +0.27 (+2.10%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$13.15 +0.02 (+0.15%) As of 05/27/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.REGENXBIO NASDAQ:RGNX$9.07 -0.64 (-6.59%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$9.15 +0.08 (+0.88%) As of 05/27/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.